Eumentis Therapeutics Inc.

Eumentis Therapeutics Inc. , located in the US, specializes in developing innovative treatments for neuropsychiatric disorders, primarily targeting schizophrenia with advanced therapeutic solutions. Eumentis Therapeutics Inc. was founded in 2019 and operates from Newton Center, US.

The company focuses on developing therapies for neuropsychiatric conditions. The founder Andrew Mendelsohn has experience in the health sector. In February 2023, the company raised USD 20 mn in a Series B funding round, which constitutes the total amount raised to date. Eumentis Therapeutics develops innovative treatments for neuropsychiatric disorders, placing a strong emphasis on schizophrenia.

Their main product, EM-221, is a phosphodiesterase 10A (PDE10A) inhibitor aimed at enhancing signaling in the brain, specifically in the striatum. This treatment addresses both positive symptoms, such as hallucinations, and negative symptoms, including social withdrawal and emotional blunting, and is expected to enter clinical studies in the second half of 2025 for schizophrenia, targeting a global market that spans North America, Europe, and other regions with high prevalence of these disorders. Eumentis Therapeutics operates within a B2B model, primarily servicing healthcare providers, hospitals, and research institutions. Revenue is generated through strategic partnerships and collaborations that grant clients access to EM-221 and potential future products.

The company's pricing structure is anticipated to reflect the advanced nature of its treatments and the efficacy in managing complex neuropsychiatric symptoms. Following the Series B funding round in February 2023, which raised USD 20 mn, Eumentis Therapeutics plans to utilize these funds to support clinical trials for its lead product, EM-221. The company is also looking to expand its market reach within North America and Europe, aiming to launch their therapeutic solutions by the second half of 2025.